Invention Application
- Patent Title: ANTI-AXL ANTIBODIES AND USES THEREOF
- Patent Title (中): 抗轴抗体及其用途
-
Application No.: US14127416Application Date: 2012-06-22
-
Publication No.: US20140227283A1Publication Date: 2014-08-14
- Inventor: Bruno Robert , Benedicte Fauvel , Gwenael Cheve , Aziz Yasri , Christel Larbouret , Wilhem Leconet , Thierry Chardes , Christian Larroque , Andre Pelegrin
- Applicant: Bruno Robert , Benedicte Fauvel , Gwenael Cheve , Aziz Yasri , Christel Larbouret , Wilhem Leconet , Thierry Chardes , Christian Larroque , Andre Pelegrin
- Applicant Address: FR Paris FR Montpellier Cedex 5 FR Montpellier Cedex 6 FR Montpellier Cedex 4
- Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale),Institut Regional du Cancer de Montpellier-Val d'Aurelle,UNIVERSITE DE MONTPELLIER 1,OriBase Pharma
- Current Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale),Institut Regional du Cancer de Montpellier-Val d'Aurelle,UNIVERSITE DE MONTPELLIER 1,OriBase Pharma
- Current Assignee Address: FR Paris FR Montpellier Cedex 5 FR Montpellier Cedex 6 FR Montpellier Cedex 4
- Priority: EP11305792.1 20110622
- International Application: PCT/EP2012/062115 WO 20120622
- Main IPC: C07K16/28
- IPC: C07K16/28 ; G01N33/68 ; G01N33/574
Abstract:
The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.
Public/Granted literature
- US09409988B2 Anti-Axl antibodies and uses thereof Public/Granted day:2016-08-09
Information query
